Head-to-head evidence
Aclidinium bromide vs fluticasone furoate/umeclidinium/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Covis Pharma
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo and used trough FEV1, an accepted clinical lung-function endpoint for COPD, as its primary outcome at 12 and 28 weeks. Aclidinium showed higher reported mean FEV1 values at both time points, but because statistical significance for the primary comparisons is not reported, the result is considered unclear rather than definitively met.
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · fluticasone furoate/umeclidinium/vilanterol's landscape